3D Medicines, Inc. (HK:1244)
:1244
Top Page
3D Medicines, Inc.
(1244)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$5.50
▼(-10.42% Downside)
Action:UpgradedDate:11/19/25
The overall stock score is primarily influenced by financial performance challenges, including negative margins and reliance on external financing. Technical indicators suggest a bearish trend, but oversold conditions could lead to a rebound. Valuation metrics are weak due to ongoing losses and lack of dividends.
Positive Factors
Strong cash position
A strong cash and short-term investment base provides a durable runway for costly oncology R&D and clinical programs, reducing near-term refinancing pressure. This supports continued product development and strategic flexibility over the next several quarters.
Negative Factors
Negative operating and free cash flow
Persistently negative operating and free cash flow indicate the business cannot self-fund growth or clinical programs, increasing reliance on external capital. Over months this undermines financial flexibility and raises execution risk for long-duration drug development projects.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position
A strong cash and short-term investment base provides a durable runway for costly oncology R&D and clinical programs, reducing near-term refinancing pressure. This supports continued product development and strategic flexibility over the next several quarters.
Read all positive factors
3D Medicines, Inc. (1244) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.06B
Dividend YieldN/A
Average Volume (3M)393.13K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth-8.43%
EPS Growth64.33%
CountryHK
Employees191
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding258,177,000
10 Day Avg. Volume535,000
30 Day Avg. Volume393,126
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.89
Price to Sales (P/S)1.56
P/FCF Ratio-2.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
3D Medicines, Inc. Business Overview & Revenue Model
Company Description
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the for...
How the Company Makes Money
3D Medicines, Inc. generates revenue primarily through the sale of its pharmaceutical products and therapies, which are marketed to healthcare providers and institutions. The company may also derive income from licensing agreements with other phar...
3D Medicines, Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 448.39M | 445.65M | 634.95M | 567.39M | 60.26M | 0.00 |
| Gross Profit | 373.68M | 371.74M | 524.01M | 525.18M | 55.98M | 0.00 |
| EBITDA | -199.91M | -226.95M | -529.23M | -1.03B | -1.45B | -303.35M |
| Net Income | -168.50M | -182.66M | -524.70M | -1.02B | -1.43B | -635.38M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 1.22B | 1.43B | 1.33B | 1.06B | 496.22M |
| Cash, Cash Equivalents and Short-Term Investments | 447.10M | 840.98M | 996.58M | 942.03M | 824.48M | 414.26M |
| Total Debt | 162.97M | 237.62M | 282.43M | 175.70M | 3.15B | 1.67B |
| Total Liabilities | 509.91M | 512.54M | 558.20M | 436.65M | 3.33B | 1.77B |
| Stockholders Equity | 716.15M | 785.06M | 936.74M | 943.00M | -2.24B | -1.27B |
Cash Flow | ||||||
| Free Cash Flow | -55.38M | -249.60M | -150.74M | -332.76M | -433.46M | -289.48M |
| Operating Cash Flow | -48.66M | -210.58M | -144.41M | -278.78M | -377.08M | -278.33M |
| Investing Cash Flow | -91.12M | 17.95M | -187.58M | -242.11M | -98.87M | -20.48M |
| Financing Cash Flow | -100.33M | -33.92M | 304.51M | 408.41M | 840.08M | 607.39M |
3D Medicines, Inc. Technical Analysis
Neutral
6.14
Price Trends
4.25
Negative
4.71
Negative
5.70
Negative
Market Momentum
-0.03
Negative
50.32
Neutral
43.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Neutral. The current price of 6.14 is above the 20-day moving average (MA) of 3.99, above the 50-day MA of 4.25, and above the 200-day MA of 5.70, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of 43.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1244.
3D Medicines, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$5.60B | -5.30 | 2.04% | ― | 1447.56% | ― | |
43 Neutral | HK$1.02B | -4.22 | -14.48% | ― | ― | -41.48% | |
43 Neutral | HK$1.25B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
41 Neutral | HK$1.06B | -2.53 | -22.45% | ― | -8.43% | 64.33% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:1244
3D Medicines, Inc.
4.10
0.58
16.48%
HK:2137
Brii Biosciences Limited
1.42
-0.23
-13.94%
HK:6998
Genor Biopharma Holdings Limited
2.79
0.97
53.30%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.40
212.50%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.80
57.55%
HK:6628
Transcenta Holding Limited
2.82
1.68
147.37%
3D Medicines, Inc. Corporate Events
3D Medicines Appoints Veteran Capital Markets Executive as New CFO
Jan 12, 2026
3D Medicines Inc. has announced a leadership change in its finance function, with long-serving chief financial officer Zhang Jing resigning and experienced capital markets professional Lu Xiaohao taking over the role, effective immediately. Lu bri...
3D Medicines’ Envafolimab NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA
Jan 9, 2026
3D Medicines Inc. announced that China’s National Medical Products Administration has accepted its new drug application for Envafolimab (KN035) in combination with the GEMOX regimen as a first-line treatment for unresectable or metastatic bi...
3D Medicines Wins Third Orphan-Drug Designation for Envafolimab in Gastric Cancers
Dec 22, 2025
3D Medicines has received orphan-drug designation for its PD-L1 inhibitor Envafolimab (KN035) for the treatment of gastric cancer and gastro-esophageal junction cancer, marking the third such designation for the product after biliary tract cancer ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.